- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03324412
Efficacy and Safety of TwHF and MTX in Patients With Rheumatoid Arthritis
October 25, 2017 updated by: Quan Jiang, Guang'anmen Hospital of China Academy of Chinese Medical Sciences
A 24-Week, Multicenter ,Double Blind, Randomized Study to Determine the Effects and Security of TwHF and MTX Treating Rheumatoid Arthritis
Rheumatoid Arthritis (RA) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability.
It has been confirmed that Tripterygium Wilfordii has effects of anti-inflammatory, immunosuppressive and cartilage protection.
This is a multicenter ,double Blind, randomized study to evaluated the efficacy and safety of Tripterygium Wilfordii in treating of patients with rheumatoid arthritis (RA) and establish a prediction model for Tripterygium Wilfordii response of rheumatoid arthritis (RA).
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Detailed Description
Two arms were included in this study.
Active Comparator: treatment of MTX Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F(TwHF)placebo.Experimental: treatment of TwHF Patients were treated with methotrexate (MTX) and Tripterygium wilfordii Hook F(TwHF).
Study Type
Interventional
Enrollment (Anticipated)
216
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Jiang Quan, MD
- Phone Number: 010-88001060
- Email: doctor@126.com
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
45 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Diagnosed with rheumatoid arthritis as determined by the 1987 or 2010 ACR classification criteria;
- No male or female fertility requirements, or around menopause women;
- Patients with mild-to-moderate activity, 2.6 < DAS28≤5.1;
- No serious system involved, such as severe pericardial effusion, interstitial lung disease, renal tubular acidosis, atrophic gastritis, autoimmune liver disease, etc;
- Within a month before the selected participants did not attend any drugs
Exclusion Criteria:
- Patients with cancer or other malignant disease such as cardiovascular, hematopoietic, liver and kidney disease, and psychopath
- Active or chronic infection, including HIV, hepatitis C virus, hepatitis B virus, tuberculosis
- Previous treated with tripterygii, glucocorticoid or biologic disease-modifying antirheumatic drug (DMARD) in 3 months.
- Previous treated with Tripterygium Wilfordii or MTX
- Patients with retinopathy.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Treatment of MTX
Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F(TwHF)placebo.
|
Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F(TwHF)placebo:20mg, 3 times a day, oral, for 24 weeks.
|
Experimental: Treatment of MTX and TwHF
Patients were treated with methotrexate (MTX)and Tripterygium wilfordii Hook F(TwHF).
|
Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F(TwHF):20mg, 3 times a day, oral, for 24 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The change from Baseline to week 24 in Disease Activity Score (DAS28)
Time Frame: 0 weeks, 4 weeks,12 weeks, 24 weeks,52 weeks
|
Disease Activity Score for 28-joint counts was based on the erythrocyte sedimentation rate(ESR) (DAS28-4[ESR])
|
0 weeks, 4 weeks,12 weeks, 24 weeks,52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The proportion of patients achieving ACR20/50/70
Time Frame: 0 weeks, 4 weeks,12 weeks, 24 weeks
|
ACR20/50/70 is referred to American College of Rheumatology Criteria
|
0 weeks, 4 weeks,12 weeks, 24 weeks
|
The change in Health Assessment Questionnaire (HAQ) score
Time Frame: 0 weeks, 4 weeks,12 weeks, 24 weeks,52 weeks
|
HAQ scores ranges from 0 to 3, with higher scores indicating greater disability
|
0 weeks, 4 weeks,12 weeks, 24 weeks,52 weeks
|
The change in Sharp score
Time Frame: 0 week,24 weeks,52 weeks
|
The change in X-Ray from baseline to week 24 and 52.
|
0 week,24 weeks,52 weeks
|
The number of adverse events
Time Frame: 24 weeks
|
The number of adverse events that are related to treatment
|
24 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 28, 2017
Primary Completion (Anticipated)
May 31, 2019
Study Completion (Anticipated)
September 30, 2019
Study Registration Dates
First Submitted
October 25, 2017
First Submitted That Met QC Criteria
October 25, 2017
First Posted (Actual)
October 27, 2017
Study Record Updates
Last Update Posted (Actual)
October 27, 2017
Last Update Submitted That Met QC Criteria
October 25, 2017
Last Verified
October 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Z161100000516020-2
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
Universidad Autonoma de Nuevo LeonCompletedRheumatoId ArthritisMexico
-
Hamad Medical CorporationUnknownRHEUMATOID ARTHRITISQatar
Clinical Trials on Treatment of MTX
-
Guang'anmen Hospital of China Academy of Chinese...Unknown
-
Guang'anmen Hospital of China Academy of Chinese...UnknownRheumatoid ArthritisChina
-
Organon and CoCompletedPostmenopausal Osteoporosis
-
Chugai PharmaceuticalCompletedRheumatoid Arthritis
-
Merck Sharp & Dohme LLCIntegrated Therapeutics GroupCompleted
-
Mozart Therapeutics Australia Pty LtdNot yet recruitingType 1 Diabetes | Celiac Disease | Healthy VolunteersAustralia
-
Grünenthal GmbHCompletedOsteoarthritis, KneeBelgium
-
Antares Pharma Inc.Completed
-
Alimentiv Inc.AbbottTerminated
-
Janssen Research & Development, LLCCompletedArthritis, RheumatoidPoland, Ukraine, Colombia, Bulgaria, United States, Singapore, Russian Federation, Argentina, Hungary, Chile, Czech Republic